Adalimumab Market Report 2024 (Global Edition)

Global Adalimumab Market Report 2024 Market Size Split by Type (Biologics, Biosimilars), by Route of Administration (Oral, Parenteral, Others), by Indication (Rheumatoid Arthritis, Ankylosing Spondyli...

Adalimumab Market Report Description

We have various report editions of Adalimumab Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Adalimumab Market Insights Video

Competitive Landscape of the Adalimumab Market

The major players rapidly evolve with new strategies to attain a competitive edge and capture significant market share. The major Adalimumab market participants emphasize expanding creative offerings to serve a large consumer base and gain a competitive benefit.

Adalimumab Industry News

• February 2022, Pfizer Inc. said that the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb), an interchangeable biosimilar to Humira (adalimumab), has been accepted for consideration by the US Food and Drug Administration (FDA).

(Source: www.pfizer.com/news/press-release/press-release-detail/fda-accepts-review-pfizers-supplemental-application)

Top Companies Market Share in Adalimumab Industry: (In no particular order of Rank)

• F. Hoffmann-La Roche Ltd. 
• Mylan N.V. 
• Teva Pharmaceutical Industries Ltd.
• Sanofi 
• Pfizer Inc. 
• GlaxoSmithKline plc 
• Novartis AG 
• Zydus Cadila 
• Biogen 
• Fresenius Kabi AG 
• Boehringer Ingelheim International GmbH. 
• Amgen Inc. 
• AbbVie Inc. 
• Abbott 
• CELLTRION INC. 
• Samsung Bioepis 
• Coherus BioSciences 
• Innovent Biologics Inc. 
• Hetero Biopharma Ltd. 
• Reliance Life Sciences 
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

In terms of revenue, the North American Adalimumab Market share was 40% of the total market

According to Cognitive Market Research, North America led the market in 2023, generating around 40% of worldwide revenue. Due in large part to its sophisticated healthcare system, high incidence of autoimmune illnesses, and substantial R&D investments, North America is a major player in the expanding Adalimumab market. North America is positioned as a prominent player in the market, influencing the trajectory of Adalimumab usage in treating various chronic inflammatory disorders due to the region's powerful pharmaceutical sector and emphasis on novel therapeutics.

Europe is the fastest-growing category as its dedication to patient care and pharmaceutical innovation makes it a significant player in the market, impacting the growing acceptance and use of Adalimumab for treating various chronic inflammatory diseases.

The current report Scope analyzes Adalimumab Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Adalimumab Market

According to Cognitive Market Research, the global Adalimumab market size was estimated at USD 21512.2 Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 8604.88 million in 2023 and will grow at a compound annual growth rate (CAGR) of 4.1% from 2023 to 2030. North America's sophisticated healthcare system and high incidence of autoimmune illnesses make it a dominant player in the ADAlimumab industry. The demand for Adalimumab is driven by the region's diversified patient population with chronic inflammatory diseases. In particular, the growing number of specialized clinics focused on autoimmune disorders plays a major role in the medication's uptake. These clinics' extensive medical knowledge complements patients' intricate demands. Finally, the market's growth trajectory is shaped by North America's significant involvement in the use of Adalimumab, which demonstrates a dedication to cutting-edge treatments and patient-centered care while addressing the changing healthcare landscape for people with chronic inflammatory disorders.

• According to Cognitive Market Research, the US had a major share in the Adalimumab market with a market size of USD 6789.25 million in 2023 and is projected to grow at a CAGR of 3.9% during the forecast period. This is majorly due to the as well as growing knowledge of cutting-edge medicines. 
• The Canada Adalimumab market had a market share of USD 1032.59 million in 2023 and is projected to grow at a CAGR of 4.9% during the forecast period. This is due to its developed healthcare system. 
• The Mexico Adalimumab market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 783.04 million in 2023.

Europe Adalimumab Market

According to Cognitive Market Research, with a market value of USD 21512.2 million in 2023 and projected to expand at a compound annual growth rate (CAGR) of 4.4% from 2023 to 2030, Europe accounted for a share of over 30% of the global Adalimumab market size of USD 6453.66 million. Europe is a major player in the ADAlimumab market because of its developed healthcare infrastructure and high prevalence of autoimmune illnesses. The area offers an atmosphere that is favorable for Adalimumab's expansion, with an emphasis on clinics and specialist medical facilities for the management of autoimmune illnesses. The aforementioned components have a notable impact on the extensive utilization of Adalimumab in the management of several chronic inflammatory ailments. In conclusion, Europe is a critical market influencer that shapes the trajectory of Adalimumab utilization and contributes to better therapeutic outcomes for people across the region who are battling autoimmune diseases because of its dedication to pharmaceutical innovation, medical research, and patient care.

• According to Cognitive Market Research, the Germany Adalimumab market size was valued at USD 1277.82 million in 2023 and is projected to grow at a CAGR of 4.6% during the forecast period. This is majorly due to the government programs to upgrade the country's medical infrastructure. 
• The United Kingdom Adalimumab market had a market share of USD 1084.21 million in 2023 and is projected to grow at a CAGR of 5.2% during the forecast period. This is due to the nation's enormous population. 
• The France Adalimumab market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD 593.74 million in 2023.
• The Italy Adalimumab market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 555.01 million in 2023.
• The Russia Adalimumab market is projected to witness growth at a CAGR of 3.4% during the forecast period with a market size of USD 1000.32 million in 2023.
• The Spain Adalimumab market is projected to witness growth at a CAGR of 3.5% during the forecast period with a market size of USD 529.20 million in 2023.
• The Portugal Adalimumab market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD 135.53 million in 2023.
• The Luxembourg Adalimumab market is projected to witness growth at a CAGR of 4.5% during the forecast period with a market size of USD 200.06 million in 2023.
• The Greece Adalimumab market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD 77.44 million in 2023.
• The Rest of Europe Adalimumab market is projected to witness growth at a CAGR of 3.1% during the forecast period with a market size of USD 1000.32 million in 2023.

Asia Pacific Adalimumab Market

According to Cognitive Market Research, the global Adalimumab market size was estimated at USD 21512.2 Million out of which Asia Pacific held the market of more than 23% of the global revenue with a market size of USD 4947.81 million in 2023 and will grow at a compound annual growth rate (CAGR) of 7.9% from 2023 to 2030. With a changing healthcare environment and a rise in the incidence of autoimmune illnesses, Asia Pacific is emerging as a promising new market for adalimumab. There is an increasing need for Adalimumab in the area, particularly in the hospital sector where specialized treatment for autoimmune diseases is essential. The market for adalimumab is growing significantly as a result of Asia Pacific's ongoing investments in sophisticated medicines and healthcare infrastructure. In conclusion, Asia Pacific is positioned as a major market player, helping to promote the use of adalimumab for the treatment of chronic inflammatory conditions in a variety of patient populations. This is due to the region's changing healthcare ecosystem and increased awareness of autoimmune disorders.

• According to Cognitive Market Research, the China Adalimumab market size was valued at USD 2226.51 million in 2023 and is projected to grow at a CAGR of 7.4% during the forecast period. This is majorly due to the developing rates of autoimmune illnesses. 
• The India Adalimumab market had a market share of USD 593.74 million in 2023 and is projected to grow at a CAGR of 9.7% during the forecast period. This is due to the more access to healthcare. 
• The Japan Adalimumab market is projected to witness growth at a CAGR of 6.4% during the forecast period with a market size of USD 682.80 million in 2023.
• The South Korea Adalimumab market is projected to witness growth at a CAGR of 7.0% during the forecast period with a market size of USD 494.78 million in 2023.
• The Australia Adalimumab market is projected to witness growth at a CAGR of 7.6% during the forecast period with a market size of USD 257.29 million in 2023.
• The South East Asia Adalimumab market is projected to witness growth at a CAGR of 8.9% during the forecast period with a market size of USD 341.40 million in 2023.
• The Rest of Asia Pacific Adalimumab market is projected to witness growth at a CAGR of 7.7% during the forecast period with a market size of USD 351.29 million in 2023.

South America Adalimumab Market

According to Cognitive Market Research, the global Adalimumab market size was estimated at USD 21512.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 1075.61 million in 2023 and will grow at a compound annual growth rate (CAGR) of 5.3% from 2023 to 2030. Due to the rising incidence of autoimmune illnesses and the expanding healthcare sector, Latin America is becoming a significant player in the adalimumab market. The area has an increasing need for Adalimumab, with a particular emphasis on autoimmune disease specialty clinics. These clinics, which cater to the complicated needs of patients struggling with chronic inflammatory disorders, play a crucial role in the medication's adoption. In conclusion, Latin America is positioned to have a major influence in the Adalimumab market, influencing the trajectory of its utilization and helping to improve treatment outcomes throughout the region thanks to its dedication to healthcare developments and emphasis on patient-centric care.

• According to Cognitive Market Research, the Brazil Adalimumab market size was valued at USD 460.36 million in 2023 and is projected to grow at a CAGR of 5.9% during the forecast period. This is majorly due to the thriving pharmaceutical sector. 
• The Argentina Adalimumab market had a market share of USD 180.70 million in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period. This is due to the growing ubiquity. 
• The Colombia Adalimumab market is projected to witness growth at a CAGR of 5.1% during the forecast period with a market size of USD 95.73 million in 2023.
• The Peru Adalimumab market is projected to witness growth at a CAGR of 5.5% during the forecast period with a market size of USD 88.20 million in 2023.
• The Chile Adalimumab market is projected to witness growth at a CAGR of 5.6% during the forecast period with a market size of USD 77.44 million in 2023.
• The Rest of Latin America Adalimumab market is projected to witness growth at a CAGR of 4.4% during the forecast period with a market size of USD 173.17 million in 2023.

Middle East and Africa Adalimumab Market

According to Cognitive Market Research, the global Adalimumab market size was estimated at USD 21512.2 Million out of which Middle East and Africa held the major market of more than 2% of the global revenue with a market size of USD 430.24 million in 2023 and will grow at a compound annual growth rate (CAGR) of 5.6% from 2023 to 2030. The Middle East and Africa region is experiencing growth in the Adalimumab market due to the expanding healthcare sector and an increase in the prevalence of autoimmune illnesses. Adalimumab is in greater demand in the area, especially in hospitals where it is essential for the treatment of autoimmune diseases. The Middle East and Africa are well-positioned to play a significant role in the growing Adalimumab market due to their emphasis on cutting-edge healthcare infrastructure and increasing accessibility to cutting-edge medicines. In summary, the region's dedication to improving healthcare and meeting the requirements of people with chronic inflammatory disorders highlights its expanding power in determining the course of Adalimumab use for better patient outcomes among a variety of demographics.

• According to Cognitive Market Research, the GCC Countries Adalimumab market size was valued at USD 184.14 million in 2023 and is projected to grow at a CAGR of 6.4% during the forecast period. This is majorly due to the country's high autoimmune disease prevalence. 
• The South Africa Adalimumab market had a market share of USD 67.98 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period. This is due to the sophisticated healthcare system. 
• The Egypt Adalimumab market is projected to witness growth at a CAGR of 5.9% during the forecast period with a market size of USD 45.18 million in 2023.
• The Turkey Adalimumab market is projected to witness growth at a CAGR of 5.1% during the forecast period with a market size of USD 37.00 million in 2023.
• The Nigeria Adalimumab market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD 45.18 million in 2023.
• The Rest of MEA Adalimumab market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 50.77 million in 2023.

Adalimumab Market Analysis

Adalimumab Type Segment Analysis

According to Cognitive Market Research, Biologics holds a prominent market share. The fact that Adalimumab is classified as a biologic—more precisely, as a tumor necrosis factor (TNF) inhibitor—highlights the targeted nature of its therapeutic intervention. With biologics becoming more well-known for their accuracy in treating autoimmune diseases, including psoriasis and rheumatoid arthritis, the market for Adalimumab is expanding significantly. The ongoing emphasis on biologic medicines upholds Adalimumab's leading role in developing novel therapeutic approaches.

Biosimilars are the fastest-growing category over the forecast period. Biosimilars aid in market expansion by providing Adalimumab-like efficacy at a cheaper price. The use of Adalimumab biosimilars is encouraging competition and affordability as healthcare systems throughout the world place a higher priority on economical solutions. This propels the expansion and accessibility of Adalimumab-based treatments for various autoimmune disorders.

• Biologics
• Biosimilars

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Adalimumab Industry. Request a Free Sample PDF!

Adalimumab Route of Administration Segment Analysis

According to Cognitive Market Research, Oral holds a prominent market share. Creating oral substitutes may improve patient convenience and increase the number of users. This route supports the market's ability to adapt to patient preferences by providing a more convenient and approachable method of administration, which in turn helps the Adalimumab market expand.

Parenteral is the fastest-growing category over the forecast period; Adalimumab's proven effectiveness when administered parenterally, together with the practicality and dependability of this mode of administration, all contribute to the drug's widespread use. Therefore, the growing market for Adalimumab in treating numerous autoimmune disorders is driven by the emphasis on parenteral delivery.

• Oral
• Parenteral
• Others

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Adalimumab Indication Segment Analysis

According to Cognitive Market Research, Rheumatoid Arthritis held the major market share over the forecast period. Adalimumab, a strong inhibitor of tumor necrosis factor (TNF), alleviates patients' pain and inflammation by effectively managing RA symptoms. The drug's extensive use in the treatment of RA is indicative of its effectiveness, which has helped drive the market for Adalimumab to grow as it meets the changing demands of those living with this inflammatory disease.

Chronic Plaque Psoriasis is the fastest-growing category over the forecast period. Because of its effectiveness as a tumor necrosis factor (TNF) inhibitor, Adalimumab is a key component in managing this skin condition, offering notable symptom alleviation. The drug's increasing use in treating chronic plaque psoriasis demonstrates its efficacy. It propels the market upward by satisfying patients' changing needs for cutting-edge and significant dermatological health remedies.

• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Chronic Plaque Psoriasis
• Crohn's Disease
• Ulcerative Colitis
• Psoriatic Arthritis
• Juvenile Idiopathic Arthritis
• Hidradenitis Suppurativa
• Non-Infectious Intermediate
• Others

Adalimumab End-User Segment Analysis

According to Cognitive Market Research, Hospitals hold a prominent market share. The rising incidence of conditions such as psoriasis and rheumatoid arthritis leads to increased use of Adalimumab in hospital environments. The drug is widely used in hospitals due to its advanced medical infrastructure and specialized medical knowledge, which supports the growth of the Adalimumab market as hospitals prioritize providing patients with autoimmune illnesses with efficient therapy.

Specialty Clinics are the fastest-growing category over the forecast period. These clinics help explain why Adalimumab is becoming increasingly popular by providing diagnostics, customized treatment programs, and specialist knowledge. Specialty clinics' targeted strategies complement the intricate requirements of patients suffering from autoimmune diseases, propelling the development of Adalimumab as the treatment of choice in these medical environments.

• Hospitals
• Specialty Clinics
• Homecare
• Others

Adalimumab Dosage Form Segment Analysis

According to Cognitive Market Research, tablets hold a prominent market share. Although Adalimumab has always been given by injection, investigating oral forms like tablets may improve patient convenience and increase the drug's potential market share. This change reflects the market's adaptability to patient preferences by providing a more convenient and accessible form of administration, supporting the market's overall expansion for adalimumab.

The injection is the fastest-growing category over the forecast period. Adalimumab is widely used since it is known to help treat autoimmune diseases, and injectable delivery is convenient and reliable. Adalimumab is a trustworthy parenteral medication that is increasingly in demand due to its ability to serve a wide range of patient needs in the management of chronic inflammatory illnesses. The emphasis on injection administration fuels this.

• Tablet
• Injection
• Solution
• Others

Author's Detail

Sneha Mali

Research Analyst at Cognitive Market Research

LinkedIn

Profile

I am a research analyst working in various domains including the Consumer Goods domain, and my primary responsibility is to conduct thorough research on various subjects and provide valuable insights to support client requirements. I have knowledge of research methodologies, and data mining which enables me to analyze large data sets, draw meaningful conclusions, and communicate them effectively. I stay up-to-date with the latest research trends, methodologies, and technologies to ensure that my research is accurate, relevant, and impactful.

Author's Conclusion